Stephen Mitchener - Aug 31, 2022 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role: SVP, Chief Business Officer
Signature: /s/ Nancy Smith as Attorney-in-Fact for Stephen Mitchener
Stock symbol: KPTI
Transactions as of: Aug 31, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/1/2022, 09:03 PM
Previous filing: Mar 2, 2022
Next filing: Mar 2, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KPTI	Common Stock	Award	$0	+20K	+39.57%	$0.00	70.5K	Aug 31, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KPTI	Stock Option (right to buy)	Award	$0	+30K		$0.00	30K	Aug 31, 2022	Common Stock	30K	$5.06	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.
F2	This option was granted on August 31, 2022 pursuant to the Plan. The shares underlying this option vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.